Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Sep 14 2011

Tengion, Inc. (Nasdaq: TNGN) today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit™, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  

"We are pleased to resume screening procedures to enroll the next patient in our ongoing trial," said Sunita Sheth, M.D., Chief Medical Officer and Vice President Clinical and Regulatory Affairs of Tengion. "We anticipate enrolling our fourth patient during the fourth quarter of this year, followed by another patient during the first quarter of 2012.  After enrolling the fifth patient and safety data permitting, we intend to discuss with clinical investigators and the Data Safety Monitoring Board a reduction in the amount of time between future patient implants."

Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present this update at the Rodman & Renshaw 13th Annual Healthcare Conference later today at 1:35 pm EDT.